AN1792
AN1792
A synthetic form of the 42-residue A beta protein seen in Alzheimer’s disease (AD) brains. It prevents appearance of amyloid plaques and the neuropathology characteristic of autosomal dominant AD in young PDAPP mice; immunisation of older mice with established AD-like pathology resulted in a marked reduction or stopped disease progression.AN-792 made it to early trials as an immune therapy for AD; some patients developed CNS inflammation; trials were halted in 2002.